Derek Dinart
Overview
Explore the profile of Derek Dinart including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
22
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Baudelin C, Sargos P, Dinart D, Hennequin C, Teyssonneau D, Meynard L, et al.
Crit Rev Oncol Hematol
. 2024 Nov;
205:104557.
PMID: 39580059
Background And Objective: For selected patients with muscle-invasive bladder cancer (MIBC), trimodal therapy (TMT) incorporating transurethral resection of the tumor and chemoradiotherapy is an alternative to radical cystectomy. Concurrent chemotherapy...
2.
Dinart D, Rondeau V, Bellera C
Pharm Stat
. 2024 Jul;
23(6):1084-1094.
PMID: 39014905
Biomarker-guided therapy is a growing area of research in medicine. To optimize the use of biomarkers, several study designs including the biomarker-strategy design (BSD) have been proposed. Unlike traditional designs,...
3.
Dinart D, Bellera C, Rondeau V
J Biopharm Stat
. 2024 Feb;
35(2):241-256.
PMID: 38334044
In epidemiology and clinical research, recurrent events refer to individuals who are likely to experience transient clinical events repeatedly over an observation period. Examples include hospitalizations in patients with heart...
4.
Toulmonde M, Dinart D, Brahmi M, Verret B, Jean-Denis M, Ducimetiere F, et al.
Cancers (Basel)
. 2023 Sep;
15(17).
PMID: 37686582
Gastrointestinal stromal tumors (GIST) are rare mesenchymal tumors characterized by or mutations. Over three decades, significant changes in drug discovery and loco-regional (LR) procedures have impacted treatment strategies. We assessed...
5.
Meynard L, Dinart D, Delaunay B, Flechon A, Saldana C, Lefort F, et al.
Eur J Cancer
. 2022 Sep;
175:43-53.
PMID: 36088671
Background: Recent studies suggest improvements in response to salvage chemotherapy (CT) after immune checkpoint inhibitors (ICIs) in several types of cancer. Our objective was to assess the efficacy of chemotherapy...
6.
Italiano A, Dinart D, Soubeyran I, Bellera C, Esperou H, Delmas C, et al.
BMC Cancer
. 2021 Nov;
21(1):1180.
PMID: 34740331
Background: Soft-tissue sarcomas (STS) represent a heterogeneous group of rare tumors including more than 70 different histological subtypes. High throughput molecular analysis (next generation sequencing exome [NGS]) is a unique...
7.
Dinart D, Bellera C, Rondeau V
Biometrics
. 2021 Jul;
78(4):1662-1673.
PMID: 34242412
A key issue when designing clinical trials is the estimation of the number of subjects required. Assuming for multicenter trials or biomarker-stratified designs that the effect size between treatment arms...
8.
Auzanneau C, Bacq D, Bellera C, Blons H, Boland A, Boucheix M, et al.
ESMO Open
. 2020 Jul;
5(4).
PMID: 32713836
Background: Whole exome sequencing and RNA sequencing (WES/RNASeq) should now be implemented in the clinical practice in order to increase access to optimal care for cancer patients. Providing results to...
9.
Bourcier K, Dinart D, Cesne A, Honore C, Meeus P, Blay J, et al.
Oncologist
. 2019 Apr;
24(7):e559-e564.
PMID: 31015315
Background: Soft-tissue sarcomas (STSs) are a group of rare cancers that can occur at any age. Prognostic outcomes of patients with STS are usually established at the time of the...
10.
Savina M, Gourgou S, Italiano A, Dinart D, Rondeau V, Penel N, et al.
Crit Rev Oncol Hematol
. 2018 Feb;
123:21-41.
PMID: 29482777
Background: In cancer randomized controlled trials (RCT), alternative endpoints are increasingly being used in place of overall survival (OS) to reduce sample size, duration and cost of trials. It is...